MicroRNA-27a-3p is a negative regulator of lung fibrosis by targeting myofibroblast differentiation

American Journal of Respiratory Cell and Molecular Biology

Volumn 54, Issue 6, 2016, Pages 843-852

  Cui, Huachun ^a   Banerjee, Sami ^a   Xie, Na ^a   Ge, Jing ^a   Liu, Rui Ming ^a   Matalon, Sadis ^b   Thannickal, Victor J ^a   Liu, Gang ^a  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Lung fibrosis; MicroRNA 27a 3p; Myofibroblast; Smad; smooth muscle actin

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; FIBRONECTIN; MICRORNA; MICRORNA 27A 3P; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; SMALL INTERFERING RNA; SMOOTH MUSCLE ACTIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; ACTA2 PROTEIN, HUMAN; ACTIN; MIRN27 MICRORNA, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN TISSUE; LUNG FIBROBLAST; LUNG FIBROSIS; MOUSE; MYOFIBROBLAST; NEGATIVE FEEDBACK; NONHUMAN; PROMOTER REGION; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN INDUCTION; PROTEIN RNA BINDING; PROTEIN TRANSPORT; SMOOTH MUSCLE CONTRACTILITY; TISSUE DIFFERENTIATION; TRANSCRIPTION INITIATION SITE; UPREGULATION; ANIMAL; C57BL MOUSE; CELL DIFFERENTIATION; DRUG EFFECTS; FIBROSING ALVEOLITIS; GENETICS; HEK293 CELL LINE; LENTIVIRINAE; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY;

ACTINS; ANIMALS; BASE SEQUENCE; CELL DIFFERENTIATION; HEK293 CELLS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LENTIVIRUS; MICE, INBRED C57BL; MICRORNAS; MYOFIBROBLASTS; SMAD2 PROTEIN; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84988850898     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2015-0205OC     Document Type: Article

References (48)

1. Thannickal VJ, Zhou Y, Gaggar A, Duncan SR. Fibrosis: ultimate and proximate causes. J Clin Invest 2014;124:4673-4677.
2. Barkauskas CE, Noble PW. Cellular mechanisms of tissue fibrosis. 7. New insights into the cellular mechanisms of pulmonary fibrosis. Am J Physiol Cell Physiol 2014;306:C987-C996.
3. Noble PW, Barkauskas CE, Jiang D. Pulmonary fibrosis: patterns and perpetrators. J Clin Invest 2012;122:2756-2762.
4. Strieter RM, Mehrad B. New mechanisms of pulmonary fibrosis. Chest 2009;136:1364-1370.
5. Wolters PJ, Collard HR, Jones KD. Pathogenesis of idiopathic pulmonary fibrosis. Annu Rev Pathol 2014;9:157-179.
6. Chilosi M, Poletti V, Zamò A, Lestani M, Montagna L, Piccoli P, Pedron S, Bertaso M, Scarpa A, Murer B, et al. Aberrant Wnt/b-catenin pathway activation in idiopathic pulmonary fibrosis. Am J Pathol 2003; 162:1495-1502.
7. Yan Z, Kui Z, Ping Z. Reviews and prospectives of signaling pathway analysis in idiopathic pulmonary fibrosis. Autoimmun Rev 2014;13: 1020-1025.
8. Xu K, Moghal N, Egan SE. Notch signaling in lung development and disease. Adv Exp Med Biol 2012;727:89-98.
9. Lekkerkerker AN, Aarbiou J, van Es T, Janssen RA. Cellular players in lung fibrosis. Curr Pharm Des 2012;18:4093-4102.
10. Phan SH. The myofibroblast in pulmonary fibrosis. Chest 2002;122(6 suppl):286S-289S.
11. Scotton CJ, Chambers RC. Molecular targets in pulmonary fibrosis: the myofibroblast in focus. Chest 2007;132:1311-1321.
12. Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat ML, Gabbiani G. The myofibroblast: one function, multiple origins. Am J Pathol 2007;170:1807-1816.
13. Hinz B, Phan SH, Thannickal VJ, Prunotto M, Desmoulière A, Varga J, De Wever O, Mareel M, Gabbiani G. Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. Am J Pathol 2012;180:1340-1355.
14. Desmoulière A, Geinoz A, Gabbiani F, Gabbiani G. Transforming growth factor-b 1 induces a-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol 1993;122:103-111.
15. Jayaraman L, Massague J. Distinct oligomeric states of SMAD proteins in the transforming growth factor-b pathway. J Biol Chem 2000;275: 40710-40717.
16. Leask A, Abraham DJ.TGF-b signaling and the fibrotic response. FASEB J 2004;18:816-827.
17. Sime PJ, Xing Z, Graham FL, Csaky KG, Gauldie J. Adenovectormediated gene transfer of active transforming growth factor-b1 induces prolonged severe fibrosis in rat lung. J Clin Invest 1997;100: 768-776.
18. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993;75:843-854.
19. Stefani G, Slack FJ. Small non-coding RNAs in animal development. Nat Rev Mol Cell Biol 2008;9:219-230.
20. Bushati N, Cohen SM. microRNA functions. Annu Rev Cell Dev Biol 2007;23:175-205.
21. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-297.
22. Pandit KV, Milosevic J, Kaminski N. MicroRNAs in idiopathic pulmonary fibrosis. Transl Res 2011;157:191-199.
23. Pandit KV, Milosevic J. MicroRNA regulatory networks in idiopathic pulmonary fibrosis. Biochem Cell Biol 2015;93:129-137.
24. Pagdin T, Lavender P. MicroRNAs in lung diseases. Thorax 2012;67: 183-184.
25. Liu G, Friggeri A, Yang Y, Milosevic J, Ding Q, Thannickal VJ, Kaminski N, Abraham E. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J Exp Med 2010;207:1589-1597.
26. Cushing L, Kuang PP, Qian J, Shao F, Wu J, Little F, Thannickal VJ, Cardoso WV, LüJ. miR-29 is a major regulator of genes associated with pulmonary fibrosis. Am J Respir Cell Mol Biol 2011;45:287-294.
27. Cui H, Tan Z, Banerjee S, Xie N, Antony V, Thannickal V, Liu G. Mir-27a is a negative regulator of lung fibrosis by targeting myofibroblast [abstract]. Am J Respir Crit Care Med 2015;A4925:191.
28. Liu G, Park YJ, Abraham E. Interleukin-1 receptor-associated kinase (IRAK)-1-mediated NF-kB activation requires cytosolic and nuclear activity. FASEB J 2008;22:2285-2296.
29. Fernandez IE, Eickelberg O. The impact of TGF-b on lung fibrosis: from targeting to biomarkers. Proc Am Thorac Soc 2012;9:111-116.
30. Yang S, Cui H, Xie N, Icyuz M, Banerjee S, Antony VB, Abraham E, Thannickal VJ, Liu G. Mir-145 regulates myofibroblast differentiation and lung fibrosis. FASEB J 2013;27:2382-2391.
31. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-b family signalling. Nature 2003;425:577-584.
32. Khalil N, Whitman C, Zuo L, Danielpour D, Greenberg A. Regulation of alveolar macrophage transforming growth factor-b secretion by corticosteroids in bleomycin-induced pulmonary inflammation in the rat. J Clin Invest 1993;92:1812-1818.
33. Martin TR, Matute-Bello G. Experimental models and emerging hypotheses for acute lung injury. Crit Care Clin 2011;27:735-752.
34. Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med 1998;157:1301-1315.
35. Kuhn C, McDonald JA. The roles of the myofibroblast in idiopathic pulmonary fibrosis: ultrastructural and immunohistochemical features of sites of active extracellular matrix synthesis. Am J Pathol 1991;138:1257-1265.
36. Thannickal VJ, Toews GB, White ES, Lynch III JP, Martinez FJ. Mechanisms of pulmonary fibrosis. Annu Rev Med 2004;55:395-417.
37. Ramos C, Monta?o M, García-Alvarez J, Ruiz V, Uhal BD, Selman M, Pardo A. Fibroblasts from idiopathic pulmonary fibrosis and normal lungs differ in growth rate, apoptosis, and tissue inhibitor of metalloproteinases expression. Am J Respir Cell Mol Biol 2001;24: 591-598.
38. Xia H, Diebold D, Nho R, Perlman D, Kleidon J, Kahm J, Avdulov S, Peterson M, Nerva J, Bitterman P, et al. Pathological integrin signaling enhances proliferation of primary lung fibroblasts from patients with idiopathic pulmonary fibrosis. J Exp Med 2008;205: 1659-1672.
39. Hardie WD, Glasser SW, Hagood JS. Emerging concepts in the pathogenesis of lung fibrosis. Am J Pathol 2009;175:3-16.
40. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al. MicroRNA expression profiles classify human cancers. Nature 2005;435: 834-838.
41. Nana-Sinkam SP, Croce CM. Clinical applications for microRNAs in cancer. Clin Pharmacol Ther 2013;93:98-104.
42. Hydbring P, Badalian-Very G. Clinical applications of microRNAs. F1000 Res 2013;2:136.
43. Das S, Kumar M, Negi V, Pattnaik B, Prakash YS, Agrawal A, Ghosh B. MicroRNA-326 regulates profibrotic functions of transforming growth factor-b in pulmonary fibrosis. Am J Respir Cell Mol Biol 2014;50:882-892.
44. Liang H, Xu C, Pan Z, Zhang Y, Xu Z, Chen Y, Li T, Li X, Liu Y, Huangfu L, et al. The antifibrotic effects and mechanisms of microrna-26a action in idiopathic pulmonary fibrosis. Mol Ther 2014;22: 1122-1133.
45. Lino Cardenas CL, Henaoui IS, Courcot E, Roderburg C, Cauffiez C, Aubert S, Copin MC, Wallaert B, Glowacki F, Dewaeles E, et al. miR-199a-5p is upregulated during fibrogenic response to tissue injury and mediates TGFb-induced lung fibroblast activation by targeting caveolin-1. PLoS Genet 2013;9:e1003291.
46. Ji J, Zhang J, Huang G, Qian J, Wang X, Mei S. Over-expressed microRNA-27a and 27b influence fat accumulation and cell proliferation during rat hepatic stellate cell activation. FEBS Lett 2009;583:759-766.
47. van Rooij E, Kauppinen S. Development of microRNA therapeutics is coming of age. EMBO Mol Med 2014;6:851-864.
48. Cui H, Xie N, Thannickal VJ, Liu G. The code of non-coding RNAs in lung fibrosis. Cell Mol Life Sci 2015;72:3507-3519.